Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | Smoldering myeloma: state of the art

Irene Ghobrial • 28 Apr 2020
COMy Virtual 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma Lenalidomide

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the current state of the art in the smoldering myeloma space. The need for improved markers and terminology is outlined as is the benefit of genomic sequencing. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Irene Ghobrial

The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy 0:57
The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy
Irene Ghobrial • 6 Dec 2025
Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies 1:59
Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies
Irene Ghobrial • 6 Dec 2025
MGIP as a stable premalignant entity preceding hematologic malignancy 2:23
MGIP as a stable premalignant entity preceding hematologic malignancy
Irene Ghobrial • 6 Dec 2025
Risk stratification in smoldering myeloma: current standards and emerging advances 1:05
Risk stratification in smoldering myeloma: current standards and emerging advances
Irene Ghobrial • 17 Sep 2025

Related Videos

RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma 1:23
RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
Karthik Ramasamy • 7 Dec 2025
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma 3:53
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa • 16 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals